Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years - Université de Lorraine Access content directly
Journal Articles Clinical Gastroenterology and Hepatology Year : 2022

Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years

Bruno Arroja
  • Function : Author
Isadora Rosa
  • Function : Author
Joana Castela
  • Function : Author
Joana Moleiro
  • Function : Author
Joana Roseira
  • Function : Author
Luís Correia
  • Function : Author
Mafalda Santiago
  • Function : Author
Sandra Dias
  • Function : Author

Abstract

Subclinical intestinal inflammation is common in Crohn's disease (CD). We aimed to explore its impact in the disease progression of infliximab-treated patients and the usefulness of fecal calprotectin (FC) and C-reactive protein (CRP) as surrogate minimally invasive biomarkers.
No file

Dates and versions

hal-04168368 , version 1 (21-07-2023)

Identifiers

Cite

Fernando Magro, Diogo Magalhães, Marta Patita, Bruno Arroja, Paula Lago, et al.. Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years. Clinical Gastroenterology and Hepatology, 2022, 20 (9), pp.2059-2073.e7. ⟨10.1016/j.cgh.2021.12.004⟩. ⟨hal-04168368⟩
11 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More